2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMORecruiting
Objective is to compare field inhomogeinity between conventional titanium osteosynthesis and CFR-PEEK osteosynthesis on MR imaging. Visualisation of regions of interest will be scored and volume of field inhomogeneity will be calculated.